Genaera (GENR)
Xmark Opportunity Partners believes the company should focus its resources on the development of its MSI-1436 product candidate, which has "great promise as an anti-obesity compound." Xmark said that as long as management continues to exercise fiscal responsibility, it believes GENR's present cash position should be sufficient to allow it to "achieve a much higher valuation." Xmark Opportunity presently holds 10,166,776 shares (9.7%).

Mid 90's became intrigued with original company - Mangainin - its approach (originally frog skin) is unique and original - their anti-obesity drug - a very very longshot - is unlike all the others and intriguing - the others that I know just can't work.

broker recommendation a LONG time ago

N/A